Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

* Statistically significant reduction in sedation during the early post-operative period compared to morphine

* Statistically significant reduction in nausea in the female patient population compared to morphine

Cambridge, UK, 8th June 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company, announces additional data from post-hoc analysis of the recent Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. The Phase III data released on 20 February 2007 confirmed M6G's planned product profile and showed that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).

Sedation

Analysis of the sedation data from the M6G022 trial showed statistically significant reductions in sedation in the M6G group compared to morphine in the first four hours after surgery reaching a reduction of 15% at 4 hours (p=0.007). Discussions with clinicians support the view that this is a clinically important benefit. Opiates such as morphine are well known to induce sedation and respiratory depression. Excessive sedation in the early post-operative period is associated with depression of the respiratory system, which can, in some cases, be fatal.

Nausea in female patients

It is well established that female patients undergoing surgery have a higher risk of experiencing nausea and vomiting in the post-operative period. New data analysing the female patient group (approximately 70% of the patients in the M6G022 Phase III clinical trial) showed a statistically significant reduction in nausea in the period 6-24 hours after treatment (p=0.034). The overall incidence and severity of post-operative nausea in the M6G arm for both males and females was 27% less than that observed in the morphine arm but narrowly missed statistical significance, p=0.052 (versu
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:10/8/2008)...NDRIA, Va., Oct. 8 /PRNewswire-USNewswire/ -- The ...ople die from HIV/AIDS in,sub-Saharan Africa. More...aharan Africa have already died of AIDS. The Found...g to ensure the dying and their families,find comp...e. FHSSA,s,innovative partnering initiative links ...
(Date:10/8/2008)...anolimumab Program to be Discontinued and Headcoun...ults of its Portfolio Review; Zanolimumab Program...e Number of Employee...- Genmab A/S (OMX: GEN),announced today that it is...D4(R)). In addition, as a result of a portfolio re...
(Date:10/8/2008)... France, Oct. 8 /- Vical Incorporated...nical data and new nonclinical data,demonstrating ...oadly,applicable in DNA- and protein-based infecti...ines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,S...present the data today,Wednesday, October 8, at t...
(Date:10/7/2008)...luates the efficacy of new device for detecting po...ng colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswire...nnual Scientific Meeting in Orlando (ACG 2008), re...nted results from a,multi-institutional clinical s...R) Retroscope(R), a new device that is designed to...
Breaking Medicine Technology:In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Doctors Often Fail to Spot Suicidal Patients 1926 1Doctors Often Fail to Spot Suicidal Patients 1926 2Doctors Often Fail to Spot Suicidal Patients 1926 3Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 1Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 2USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 1USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 2SalesForce4Hire Opens New Office 1920 1SalesForce4Hire Opens New Office 1920 2
...wire-FirstCall/ -- Shire plc ,the market leader i...isorder (ADHD), announced that it will present key...t the American Psychiatric,Association (APA) annua..."The upcoming clinical research to be presented at... the science of ADHD treatment,",said Eliseo Salin...
...5, 2007 - Gemin X Biotechnologies,Inc. announced t...demonstrated that its lead compound, obatoclax (GX...l Lymphoma (MCL) cell lines and,primary cells from...molecule specifically designed to inhibit all rele...ted cancer target, thus restoring,the natural cell...
Other Medicine Technology:Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 2Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 3Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 4Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 5Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 6Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 7Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...1 or juvenile-onset diabetes also works in a rat m...g to a new report from researchers at Washington U...g that we can cure type 2 diabetes in the same way... type 2 diabetes is almost 20 times more prevalent...
...es the establishment of the Center for Celiac Dise...ose//, treat and provide support for patients and ...ac disease is unable to digest gluten, a common in...g bread, pasta and even condiments,” said Ritu Ver...
...hydrate molecules so as to prepare for an invasion...of Florida, which has been published in the curren...not only humans but viruses too that crave for car...ed that the viruses hang on to the carbohydrates t...
...f Adults Cannot Manage Without Cell Phones.The res...shire in Stoke-on-Trent, who had conducted the res...ictive behavior when it comes to their cell phones...mobile phones, he observed that some of the behavi...
Other Medicine News:Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 2Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 3Health News:Center for Celiac Disease Opens 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 3
Introducing the new Platinum 10 concentrator. The Platinum 10 delivers the reliability, performance and value advantage you have come to expect from the Platinum line of concentrators and provides an
...table Oxygen Concentrator is the most compact, lig...than 10 lbs (4.5 kg), this unit was designed to ac...e oxygen patient., ,Operating as a pulse flow... oxygen concentrator and an oxygen conserver in on...
OCD-3000 pnuematic conserving regulator.
...7.5 liters out of your five-liter concentrators. ,...igh-flow patients! , ,In many ways, the OXYMIZER...e standard conservers, because they extend oxygen ...o saturate a patient. However, they do not requir...
Medicine Products: